INTRODUCTION: Diseases caused by Streptococcus pneumoniae (pneumococcus) are a major global public health problem. Despite their importance, information on the burden of the different pneumococcal diseases is limited and estimates vary widely. OBJECTIVE AND METHODS: We critically reviewed the full economic evaluations (FEEs) on the new pneumococcal conjugate vaccines (PCVs) conducted in the European Union (EU) to assess their potential contribution to public decision making. We selected the FEEs focussed on PCV-10 and PCV-13 and published in English from January 2007 until June 2013. We screened the selected articles to assess their main methodological features using a common checklist composed of epidemiological, clinical and economic items. RESULTS: All the ten studies selected were based on modelling and the time horizon was always long term. Two studies focused on adults, the remaining eight on infants. Only one study based herd immunity on national data, eight used foreign data or modelling and the last did not consider it. National prices and tariffs were claimed to be sources for unit costs in all studies; however, half of them assumed price parity when one vaccine was not yet marketed, and the figures varied within the countries where more than one study was conducted. Conclusions supported the economic utility of pneumococcal vaccination in all studies, raising some concern only in (i) the independent study, which found that PCV-13 was borderline cost effective, and (ii) the study sponsored by both manufacturers, which estimated an incremental ratio slightly above the national threshold for both PCV-10 and PCV-13. CONCLUSION: The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by authors' choices.
INTRODUCTION: Diseases caused by Streptococcus pneumoniae (pneumococcus) are a major global public health problem. Despite their importance, information on the burden of the different pneumococcal diseases is limited and estimates vary widely. OBJECTIVE AND METHODS: We critically reviewed the full economic evaluations (FEEs) on the new pneumococcal conjugate vaccines (PCVs) conducted in the European Union (EU) to assess their potential contribution to public decision making. We selected the FEEs focussed on PCV-10 and PCV-13 and published in English from January 2007 until June 2013. We screened the selected articles to assess their main methodological features using a common checklist composed of epidemiological, clinical and economic items. RESULTS: All the ten studies selected were based on modelling and the time horizon was always long term. Two studies focused on adults, the remaining eight on infants. Only one study based herd immunity on national data, eight used foreign data or modelling and the last did not consider it. National prices and tariffs were claimed to be sources for unit costs in all studies; however, half of them assumed price parity when one vaccine was not yet marketed, and the figures varied within the countries where more than one study was conducted. Conclusions supported the economic utility of pneumococcal vaccination in all studies, raising some concern only in (i) the independent study, which found that PCV-13 was borderline cost effective, and (ii) the study sponsored by both manufacturers, which estimated an incremental ratio slightly above the national threshold for both PCV-10 and PCV-13. CONCLUSION: The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by authors' choices.
Authors: C Jokinen; L Heiskanen; H Juvonen; S Kallinen; K Karkola; M Korppi; S Kurki; P R Rönnberg; A Seppä; S Soimakallio Journal: Am J Epidemiol Date: 1993-05-01 Impact factor: 4.897
Authors: Anna S Tocheva; Johanna M C Jefferies; Henry Rubery; Jessica Bennett; Geraldine Afimeke; Joanna Garland; Myron Christodoulides; Saul N Faust; Stuart C Clarke Journal: Vaccine Date: 2011-04-17 Impact factor: 3.641
Authors: S M A A Evers; A J H A Ament; G L Colombo; H B Konradsen; R R Reinert; D Sauerland; K Wittrup-Jensen; C Loiseau; D S Fedson Journal: Eur J Clin Microbiol Infect Dis Date: 2007-08 Impact factor: 3.267
Authors: M Garcés-Sánchez; J Díez-Domingo; T Alvarez de Labiada; V Planelles; M Graullera; J Ma Baldo; L A García Llop; M García López; A Peris Vidal; Ma D Gallego García; A Ballester Sanz; C Peidro; J Villarroya; A Jubert; J Colomer Revuelta; C Casani Journal: An Pediatr (Barc) Date: 2004-02 Impact factor: 1.500
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Marie-Josée J Mangen; Mark H Rozenbaum; Susanne M Huijts; Cornelis H van Werkhoven; Douwe F Postma; Mark Atwood; Anna M M van Deursen; Arie van der Ende; Diederick E Grobbee; Elisabeth A M Sanders; Reiko Sato; Theo J M Verheij; Conrad E Vissink; Marc J M Bonten; G Ardine de Wit Journal: Eur Respir J Date: 2015-07-09 Impact factor: 16.671
Authors: Marisa Holubar; Maria Christina Stavroulakis; Yvonne Maldonado; John P A Ioannidis; Despina Contopoulos-Ioannidis Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: Farhana Aminuddin; Nur Amalina Zaimi; Mohd Shaiful Jefri Mohd Nor Sham Kunusagaran; Mohd Shahri Bahari; Nor Zam Azihan Mohd Hassan Journal: PLoS One Date: 2022-01-24 Impact factor: 3.240